Comparative Pharmacology
Head-to-head clinical analysis: CARVEDILOL versus PROPRANOLOL HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARVEDILOL versus PROPRANOLOL HYDROCHLORIDE.
CARVEDILOL vs PROPRANOLOL HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carvedilol is a nonselective beta-adrenergic receptor antagonist (beta-1, beta-2) and alpha-1 adrenergic receptor antagonist. It causes vasodilation and reduces heart rate, myocardial contractility, and blood pressure. It also has antioxidant and anti-proliferative effects.
Non-selective beta-adrenergic receptor antagonist that blocks catecholamine effects at beta-1 and beta-2 receptors, reducing heart rate, myocardial contractility, and blood pressure; also suppresses renin release and decreases sympathetic outflow.
Heart failure: Initial 3.125 mg orally twice daily, titrate every 2 weeks to 6.25 mg, 12.5 mg, then 25 mg twice daily as tolerated. Target dose: 25 mg twice daily (≤85 kg) or 50 mg twice daily (>85 kg). Hypertension: Initial 6.25 mg orally twice daily, titrate every 1-2 weeks to 12.5 mg, then 25 mg twice daily. Maximum: 50 mg twice daily.
Adults: 40 mg orally twice daily, increased gradually to 160-320 mg/day divided into 2-3 doses; maximum 640 mg/day. For hypertension: 80 mg orally twice daily, titrated to 120-240 mg/day. For migraine prophylaxis: 80 mg orally daily in divided doses, up to 160-240 mg/day. For angina: 80-320 mg orally divided into 2-4 doses. For essential tremor: 40 mg orally twice daily, up to 320 mg/day. For thyrotoxicosis: 10-40 mg orally every 6 hours. For IV use: 1-3 mg slow IV bolus (1 mg/min), repeated every 2-5 minutes up to total of 5 mg under continuous monitoring.
Clinical Note
moderateCarvedilol + Digitoxin
"Carvedilol may increase the bradycardic activities of Digitoxin."
Clinical Note
moderateCarvedilol + Deslanoside
"Carvedilol may increase the bradycardic activities of Deslanoside."
Clinical Note
moderateCarvedilol + Acetyldigitoxin
"Carvedilol may increase the bradycardic activities of Acetyldigitoxin."
Clinical Note
moderateCarvedilol + Ouabain
"Carvedilol may increase the bradycardic activities of Ouabain."
None Documented
None Documented
Terminal elimination half-life is 7-10 hours. Steady-state concentrations are achieved within 2-3 days. Clinical context: Twice-daily dosing provides consistent beta-blockade and vasodilation.
3-6 hours (terminal half-life), prolonged in hepatic impairment (up to 10-12 hours) and in elderly; half-life ~1-2 hours after IV administration; clinically, twice-daily dosing is sufficient due to sustained pharmacodynamic effect despite short half-life.
Primarily hepatic metabolism, with less than 2% excreted unchanged in urine. Metabolites are excreted in bile and feces; renal clearance of metabolites accounts for ~16% of total clearance. Fecal excretion of metabolites is ~60%.
Hepatic metabolism (extensive first-pass) to inactive metabolites; <1% excreted unchanged in urine; renal elimination of metabolites (~90% as glucuronide and sulfate conjugates); biliary/fecal elimination minimal.
Category C
Category C
Alpha/Beta-Blocker
Beta-Blocker